Tenaya Therapeutics Inc (TNYA)

$0.70 0.00 (-0.23%)
Market Cap 156.98M
Revenue (ttm) 0.00
Net Income (ttm) -90.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,209,800
Avg Vol 2,349,984
Day's Range N/A - N/A
Shares Out 224.23M
Stochastic %K 15%
Beta 2.83
Analysts Strong Sell
Price Target $9.33

Company Profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacet...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 825 6990
Address:
171 Oyster Point Boulevard, Suite 500, South San Francisco, United States
BIOVIC
BIOVIC Aug. 18 at 8:02 PM
$TNYA digestion day after yesterday’s flush .70 close, -0.23%, vol 2.17M vs 4.28M yesterday. .68 held again. range .68-.70 xbi green +0.26, so no macro tailwind. tnya trading on its own tape and it stabilized yesterday’s base rate said down another 3%+ today. actual: -0.23. supply from the sell-to-cover flow got absorbed, algos moved on, buyers back around .68 nothing broke. same range, half the volume, no follow-through selling. that’s what absorption looks like after a distribution day still watching for .72 reclaim as the trigger that says the flush is done #biovic nfa
1 · Reply
Cel55
Cel55 Aug. 18 at 6:35 PM
$TNYA In today’s market environment, the yield on the 30-year U.S. Treasury rose to 5.34%, reaching its highest level since 2007. The rise in long-term interest rates increases discount rates used in equity valuations, putting greater pressure on growth companies that have yet to achieve profitability. High-risk, clinical-stage biotechnology companies such as TNYA are particularly vulnerable to these interest-rate shocks, as higher yields can weigh on valuations, risk appetite, and the cost of future capital.
1 · Reply
Minecraftbeers
Minecraftbeers Aug. 18 at 2:59 PM
$TNYA Price: $0.6841, -2.29% today — now below the $0.70-0.95 range that held for several weeks. 1M chart: clean step-down pattern — $0.82 → $0.78 → $0.80 (bounce around Aug 11-12 Canaccord/earnings) → breakdown to $0.68-0.70 over the last few days. Volume: 1.32M today, below the 1.96M average — grind lower on light participation, not a capitulation-style sell-off. Level 2: tight spread ($0.684/$0.6841), reasonable size both sides — orderly trading, no liquidity stress. RSI: low-to-mid 40s. MACD: slightly negative. Mild bearish momentum, not oversold. 52-week range: $0.5316–$2.35. Market cap: $153.42M. Net: Canaccord fireside + Q2 earnings didn’t produce a sustained bounce — stock is lower now than before those events. NFA​​​​​​​​​​​​​​​​
0 · Reply
Lsu189
Lsu189 Aug. 18 at 2:49 PM
$TNYA @Paulfrench are you still here? Appreciate your analysis.
1 · Reply
King_of_Bio
King_of_Bio Aug. 18 at 2:40 PM
$TNYA This is a new bio...temper your expectations and expect volatility. I would NOT have this be my biggest investment yet...be SMART. Only invest what you're willing to lose.
0 · Reply
Minecraftbeers
Minecraftbeers Aug. 18 at 2:36 PM
$TNYA https://finance.yahoo.com/healthcare/articles/tenaya-therapeutics-eyes-q4-updates-080156311.html
0 · Reply
bdiddy366
bdiddy366 Aug. 18 at 2:23 PM
$TNYA is anyone worried about a potential reverse stock split? They cannot keep of these these expenses forever.
2 · Reply
Minecraftbeers
Minecraftbeers Aug. 18 at 2:19 PM
$TNYA several headlines advertising CMO and CEO selling stocks for tax withholding. That mixed with the Sub $1 and stock declining isn’t a good look. Hopefully we get some good news soon. Nonetheless I bought the dip. Keep on keeping on, no matter how bad it gets.
0 · Reply
Raumerica
Raumerica Aug. 18 at 1:15 PM
$TNYA If David Goeddel cuts and runs, I will as well. Until then, I will stick around. High institutional ownership that is increasing and I like the pipeline. 159 million market cap for 1 billion + potential in the short run… Positive TN201 and TN401 will catapult this stock.
1 · Reply
dig_THAT_girl
dig_THAT_girl Aug. 18 at 5:12 AM
$TNYA no bs, I am very new to investing . Went with biotech for the high risk high reward aspect. Four months in and I’m getting killed. Two stocks in particular, VNRX and PDSB have shit the bed. Altimmune well, whatever. I’ve put a lot into TNYA for various reasons. Yes I’ve done the DD. But, one of the most compelling reasons I believe in TNYA is based purely on gut instinct. Which ito some people is the worst reason for investing. But, assuming Biovic is a real human and not an AI bot, his zeal and investment in TNYA is compelling enough for me. That said, I’m pretty sure he’s not a bot because he laughs in Spanish. And only humans laugh naturally. So until he cuts and runs, I’m all in with my poultry 5500 shares. P.S. I’m retired on a pension and would prefer not to lose my investment, but fuck it, it’s biotech after all! LGMFrs!
2 · Reply
Latest News on TNYA
Tenaya Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 11, 2026, 12:30 PM EDT - 7 days ago

Tenaya Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference

Tenaya Therapeutics reports Q2 EPS (20c), consensus (7c)

2026-08-05T21:25:41.000Z - 13 days ago

Tenaya Therapeutics reports Q2 EPS (20c), consensus (7c)

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 5, 2026, 4:05 PM EDT - 13 days ago

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Tenaya Therapeutics Quarterly report: Q2 2026

Aug 5, 2026, 4:00 PM EDT - 13 days ago

Tenaya Therapeutics Quarterly report: Q2 2026

Tenaya Therapeutics Earnings release: Q2 2026

Aug 5, 2026, 4:00 PM EDT - 13 days ago

Tenaya Therapeutics Earnings release: Q2 2026

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Aug 4, 2026, 4:05 PM EDT - 14 days ago

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Jul 14, 2026, 9:00 PM EDT - 5 weeks ago

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Tenaya Therapeutics appoints Eric Hyllengren as CFO

2026-06-29T13:01:36.000Z - 7 weeks ago

Tenaya Therapeutics appoints Eric Hyllengren as CFO

ZURA

Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer

Jun 29, 2026, 8:30 AM EDT - 7 weeks ago

Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer

Tenaya Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 3:10 PM EDT - 2 months ago

Tenaya Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Tenaya Therapeutics Slides: FY 2026

Jun 4, 2026, 3:10 PM EDT - 2 months ago

Tenaya Therapeutics Slides: FY 2026

Tenaya Therapeutics management to meet with Piper Sandler

2026-06-03T20:45:27.000Z - 2 months ago

Tenaya Therapeutics management to meet with Piper Sandler

Tenaya Therapeutics Transcript: Study result

Jun 3, 2026, 8:00 AM EDT - 2 months ago

Tenaya Therapeutics Transcript: Study result

Tenaya Therapeutics Press release: Study result

Jun 3, 2026, 8:00 AM EDT - 2 months ago

Tenaya Therapeutics Press release: Study result

Tenaya Therapeutics Slides: Study result

Jun 3, 2026, 8:00 AM EDT - 2 months ago

Tenaya Therapeutics Slides: Study result

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

Jun 3, 2026, 7:00 AM EDT - 2 months ago

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

Jun 2, 2026, 4:30 PM EDT - 2 months ago

Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026

May 29, 2026, 8:00 AM EDT - 2 months ago

Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026

Tenaya Therapeutics Transcript: Study update

May 15, 2026, 10:30 AM EDT - 3 months ago

Tenaya Therapeutics Transcript: Study update

Tenaya Therapeutics Press release: Study update

May 15, 2026, 10:30 AM EDT - 3 months ago

Tenaya Therapeutics Press release: Study update

Tenaya Therapeutics Slides: Study update

May 15, 2026, 10:30 AM EDT - 3 months ago

Tenaya Therapeutics Slides: Study update

Tenaya reports data from RIDGE-1 Phase 1b/2 clinical trial of TN-401

2026-05-15T10:13:57.000Z - 3 months ago

Tenaya reports data from RIDGE-1 Phase 1b/2 clinical trial of TN-401

Positive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC

May 15, 2026, 6:01 AM EDT - 3 months ago

Positive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC

Tenaya Therapeutics reports Q1 EPS (9c), consensus (9c)

2026-05-07T00:34:31.000Z - 3 months ago

Tenaya Therapeutics reports Q1 EPS (9c), consensus (9c)

Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026, 4:05 PM EDT - 3 months ago

Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Tenaya Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:00 PM EDT - 3 months ago

Tenaya Therapeutics Earnings release: Q1 2026

Tenaya Therapeutics Quarterly report: Q1 2026

May 6, 2026, 4:00 PM EDT - 3 months ago

Tenaya Therapeutics Quarterly report: Q1 2026

Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026

Apr 27, 2026, 8:30 AM EDT - 4 months ago

Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026

Tenaya Therapeutics Duchenne muscular dystrophy treatment granted orphan status

2026-04-17T13:02:03.000Z - 4 months ago

Tenaya Therapeutics Duchenne muscular dystrophy treatment granted orphan status

Tenaya Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Tenaya Therapeutics Proxy statement: Proxy filing

Tenaya Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Tenaya Therapeutics Proxy statement: Proxy filing

Tenaya Therapeutics reports Q4 EPS (12c), consensus (12c)

2026-03-11T20:27:09.000Z - 5 months ago

Tenaya Therapeutics reports Q4 EPS (12c), consensus (12c)

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 11, 2026, 4:05 PM EDT - 5 months ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tenaya Therapeutics Annual report: Q4 2025

Mar 11, 2026, 4:00 PM EDT - 5 months ago

Tenaya Therapeutics Annual report: Q4 2025

Tenaya Therapeutics Earnings release: Q4 2025

Mar 11, 2026, 4:00 PM EDT - 5 months ago

Tenaya Therapeutics Earnings release: Q4 2025

Tenaya Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 1:00 PM EDT - 5 months ago

Tenaya Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Tenaya Therapeutics presents preclinical data evaluating TN-301

2026-03-09T12:41:56.000Z - 5 months ago

Tenaya Therapeutics presents preclinical data evaluating TN-301

Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy

Mar 9, 2026, 8:30 AM EDT - 5 months ago

Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy

Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments

Mar 5, 2026, 9:10 AM EST - 5 months ago

Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments

ALNY

Tenaya Therapeutics enters research collaboration with Alnylam

2026-03-05T13:52:56.000Z - 5 months ago

Tenaya Therapeutics enters research collaboration with Alnylam

ALNY

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

Mar 5, 2026, 8:30 AM EST - 5 months ago

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

ALNY

Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026

Mar 2, 2026, 4:05 PM EST - 6 months ago

Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026

Tenaya Therapeutics announces 2026 strategic priorities

2026-01-09T13:41:19.000Z - 7 months ago

Tenaya Therapeutics announces 2026 strategic priorities

Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

Jan 9, 2026, 8:30 AM EST - 7 months ago

Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

Tenaya Therapeutics price target lowered to $2 from $5 at Morgan Stanley

2026-01-08T12:46:46.000Z - 7 months ago

Tenaya Therapeutics price target lowered to $2 from $5 at Morgan Stanley

Tenaya Therapeutics price target lowered to $4 from $6 at Canaccord

2025-12-18T11:55:16.000Z - 8 months ago

Tenaya Therapeutics price target lowered to $4 from $6 at Canaccord

Tenaya Therapeutics price target lowered to $3 from $5 at H.C. Wainwright

2025-12-12T13:50:43.000Z - 8 months ago

Tenaya Therapeutics price target lowered to $3 from $5 at H.C. Wainwright

Tenaya Therapeutics price target lowered to $8 from $9 at Chardan

2025-12-12T13:20:25.000Z - 8 months ago

Tenaya Therapeutics price target lowered to $8 from $9 at Chardan

LXEO RCKT

Tenaya Therapeutics 50M share Spot Secondary priced at $1.20

2025-12-12T07:00:10.000Z - 8 months ago

Tenaya Therapeutics 50M share Spot Secondary priced at $1.20

Tenaya Therapeutics Announces Pricing of Public Offering

Dec 12, 2025, 12:16 AM EST - 8 months ago

Tenaya Therapeutics Announces Pricing of Public Offering

Tenaya Therapeutics Transcript: Study Result

Dec 11, 2025, 5:00 PM EST - 8 months ago

Tenaya Therapeutics Transcript: Study Result

Tenaya Therapeutics Press release: Study Result

Dec 11, 2025, 5:00 PM EST - 8 months ago

Tenaya Therapeutics Press release: Study Result

Tenaya Therapeutics Slides: Study Result

Dec 11, 2025, 5:00 PM EST - 8 months ago

Tenaya Therapeutics Slides: Study Result

Tenaya Therapeutics files to sell common stock, no amount given

2025-12-11T21:20:52.000Z - 8 months ago

Tenaya Therapeutics files to sell common stock, no amount given

Tenaya Therapeutics announces interim data from cohort one of RIDGE-1 trial

2025-12-11T21:16:40.000Z - 8 months ago

Tenaya Therapeutics announces interim data from cohort one of RIDGE-1 trial

Tenaya Therapeutics announces clinical hold on MyPEAK-1 trial lifted by FDA

2025-12-11T21:11:05.000Z - 8 months ago

Tenaya Therapeutics announces clinical hold on MyPEAK-1 trial lifted by FDA

Tenaya Therapeutics Announces Proposed Public Offering

Dec 11, 2025, 4:02 PM EST - 8 months ago

Tenaya Therapeutics Announces Proposed Public Offering

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

Dec 11, 2025, 4:01 PM EST - 8 months ago

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy

Dec 11, 2025, 4:01 PM EST - 8 months ago

Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy

Tenaya Therapeutics Slides: Corporate Presentation

Dec 11, 2025, 7:00 AM EST - 8 months ago

Tenaya Therapeutics Slides: Corporate Presentation

Tenaya Therapeutics Transcript: Status Update

Nov 10, 2025, 8:00 AM EST - 10 months ago

Tenaya Therapeutics Transcript: Status Update

Tenaya Therapeutics Press release: Status Update

Nov 10, 2025, 8:00 AM EST - 10 months ago

Tenaya Therapeutics Press release: Status Update

Tenaya Therapeutics Slides: Status Update

Nov 10, 2025, 8:00 AM EST - 10 months ago

Tenaya Therapeutics Slides: Status Update

Tenaya Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 10 months ago

Tenaya Therapeutics Earnings release: Q3 2025

Tenaya Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 10 months ago

Tenaya Therapeutics Quarterly report: Q3 2025

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Nov 8, 2025, 11:25 AM EST - 10 months ago

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025

Nov 4, 2025, 5:30 PM EST - 10 months ago

Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025

Tenaya Therapeutics Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Oct 21, 2025, 12:00 PM EDT - 10 months ago

Tenaya Therapeutics Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Tenaya Therapeutics Transcript: H. C. Wainwright Genetic Medicines Virtual Conference

Oct 14, 2025, 7:00 AM EDT - 11 months ago

Tenaya Therapeutics Transcript: H. C. Wainwright Genetic Medicines Virtual Conference

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

Oct 9, 2025, 4:05 PM EDT - 11 months ago

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

Oct 2, 2025, 4:05 PM EDT - 11 months ago

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

Tenaya Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 4:50 PM EDT - 1 year ago

Tenaya Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Tenaya Therapeutics Slides: Corporate Presentation

Sep 9, 2025, 7:00 AM EDT - 1 year ago

Tenaya Therapeutics Slides: Corporate Presentation

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 2, 2025, 4:05 PM EDT - 1 year ago

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Aug 31, 2025, 10:15 AM EDT - 1 year ago

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Tenaya Therapeutics Transcript: KOL Event

Aug 26, 2025, 11:30 AM EDT - 1 year ago

Tenaya Therapeutics Transcript: KOL Event

Tenaya Therapeutics Slides: Corporate Presentation

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Slides: Corporate Presentation

Tenaya Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 11:30 AM EDT - 1 year ago

Tenaya Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Tenaya Therapeutics Slides: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 11:30 AM EDT - 1 year ago

Tenaya Therapeutics Slides: Canaccord Genuity’s 45th Annual Growth Conference

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Tenaya Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Quarterly report: Q2 2025

Tenaya Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Earnings release: Q2 2025

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

Jul 30, 2025, 8:30 AM EDT - 1 year ago

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

May 13, 2025, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

Tenaya Therapeutics Earnings release: Q1 2025

May 7, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Earnings release: Q1 2025

Tenaya Therapeutics Quarterly report: Q1 2025

May 7, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Quarterly report: Q1 2025

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

Apr 24, 2025, 2:07 PM EDT - 1 year ago

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

Tenaya Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Tenaya Therapeutics Proxy statement: Proxy Filing

Tenaya Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Tenaya Therapeutics Proxy statement: Proxy Filing

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

Mar 31, 2025, 10:00 AM EDT - 1 year ago

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Mar 24, 2025, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Tenaya Therapeutics Registration statement: Registration Filing

Mar 21, 2025, 8:00 AM EDT - 1 year ago

Tenaya Therapeutics Registration statement: Registration Filing

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

Mar 19, 2025, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

Tenaya Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 12, 2025, 8:40 AM EDT - 1 year ago

Tenaya Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 10, 2025, 4:05 PM EDT - 1 year ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Tenaya Therapeutics Annual report: Q4 2024

Mar 10, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Annual report: Q4 2024

Tenaya Therapeutics Earnings release: Q4 2024

Mar 10, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Earnings release: Q4 2024

Tenaya Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 1:10 PM EST - 1 year ago

Tenaya Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

Mar 3, 2025, 8:00 AM EST - 1 year ago

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

Feb 3, 2025, 8:30 AM EST - 1 year ago

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Jan 13, 2025, 9:16 AM EST - 1 year ago

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Tenaya Therapeutics Transcript: Study Update

Dec 17, 2024, 8:00 AM EST - 1 year ago

Tenaya Therapeutics Transcript: Study Update

Tenaya Therapeutics Press release: Study Update

Dec 17, 2024, 8:00 AM EST - 1 year ago

Tenaya Therapeutics Press release: Study Update

Tenaya Therapeutics Slides: Study Update

Dec 17, 2024, 8:00 AM EST - 1 year ago

Tenaya Therapeutics Slides: Study Update

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

Dec 16, 2024, 4:30 PM EST - 1 year ago

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 4:05 PM EST - 1 year ago

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Tenaya Therapeutics Quarterly report: Q3 2024

Nov 6, 2024, 4:00 PM EST - 1 year ago

Tenaya Therapeutics Quarterly report: Q3 2024

Tenaya Therapeutics Earnings release: Q3 2024

Nov 6, 2024, 4:00 PM EST - 1 year ago

Tenaya Therapeutics Earnings release: Q3 2024

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

Tenaya Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 5, 2024, 7:00 AM EDT - 2 years ago

Tenaya Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Tenaya Therapeutics to Participate in Upcoming Investment Conferences

Sep 3, 2024, 8:30 AM EDT - 2 years ago

Tenaya Therapeutics to Participate in Upcoming Investment Conferences

Tenaya Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Tenaya Therapeutics Quarterly report: Q2 2024

Tenaya Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Tenaya Therapeutics Earnings release: Q2 2024

Tenaya Therapeutics Announces Research Leadership Updates

Jun 27, 2024, 5:00 PM EDT - 2 years ago

Tenaya Therapeutics Announces Research Leadership Updates

Tenaya Therapeutics Transcript: TD Cowen Genetic Medicines & RNA Summit

Jun 21, 2024, 11:20 AM EDT - 2 years ago

Tenaya Therapeutics Transcript: TD Cowen Genetic Medicines & RNA Summit

Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit

Jun 18, 2024, 4:30 PM EDT - 2 years ago

Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Tenaya Therapeutics Quarterly report: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

Tenaya Therapeutics Quarterly report: Q1 2024

Tenaya Therapeutics Earnings release: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

Tenaya Therapeutics Earnings release: Q1 2024

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

May 2, 2024, 5:00 PM EDT - 2 years ago

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

Tenaya Therapeutics Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Tenaya Therapeutics Proxy statement: Proxy Filing

Tenaya Therapeutics Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Tenaya Therapeutics Proxy statement: Proxy Filing

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 18, 2024, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Tenaya Therapeutics Earnings release: Q4 2023

Mar 18, 2024, 4:00 PM EDT - 2 years ago

Tenaya Therapeutics Earnings release: Q4 2023

Tenaya Therapeutics Annual report: Q4 2023

Mar 18, 2024, 4:00 PM EDT - 2 years ago

Tenaya Therapeutics Annual report: Q4 2023

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

Mar 18, 2024, 8:30 AM EDT - 2 years ago

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

Tenaya Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 12, 2024, 8:40 AM EDT - 2 years ago

Tenaya Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

Feb 26, 2024, 8:30 AM EST - 2 years ago

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

Tenaya Therapeutics Announces Pricing of Underwritten Offering

Feb 8, 2024, 8:00 AM EST - 2 years ago

Tenaya Therapeutics Announces Pricing of Underwritten Offering

BIOVIC
BIOVIC Aug. 18 at 8:02 PM
$TNYA digestion day after yesterday’s flush .70 close, -0.23%, vol 2.17M vs 4.28M yesterday. .68 held again. range .68-.70 xbi green +0.26, so no macro tailwind. tnya trading on its own tape and it stabilized yesterday’s base rate said down another 3%+ today. actual: -0.23. supply from the sell-to-cover flow got absorbed, algos moved on, buyers back around .68 nothing broke. same range, half the volume, no follow-through selling. that’s what absorption looks like after a distribution day still watching for .72 reclaim as the trigger that says the flush is done #biovic nfa
1 · Reply
Cel55
Cel55 Aug. 18 at 6:35 PM
$TNYA In today’s market environment, the yield on the 30-year U.S. Treasury rose to 5.34%, reaching its highest level since 2007. The rise in long-term interest rates increases discount rates used in equity valuations, putting greater pressure on growth companies that have yet to achieve profitability. High-risk, clinical-stage biotechnology companies such as TNYA are particularly vulnerable to these interest-rate shocks, as higher yields can weigh on valuations, risk appetite, and the cost of future capital.
1 · Reply
Minecraftbeers
Minecraftbeers Aug. 18 at 2:59 PM
$TNYA Price: $0.6841, -2.29% today — now below the $0.70-0.95 range that held for several weeks. 1M chart: clean step-down pattern — $0.82 → $0.78 → $0.80 (bounce around Aug 11-12 Canaccord/earnings) → breakdown to $0.68-0.70 over the last few days. Volume: 1.32M today, below the 1.96M average — grind lower on light participation, not a capitulation-style sell-off. Level 2: tight spread ($0.684/$0.6841), reasonable size both sides — orderly trading, no liquidity stress. RSI: low-to-mid 40s. MACD: slightly negative. Mild bearish momentum, not oversold. 52-week range: $0.5316–$2.35. Market cap: $153.42M. Net: Canaccord fireside + Q2 earnings didn’t produce a sustained bounce — stock is lower now than before those events. NFA​​​​​​​​​​​​​​​​
0 · Reply
Lsu189
Lsu189 Aug. 18 at 2:49 PM
$TNYA @Paulfrench are you still here? Appreciate your analysis.
1 · Reply
King_of_Bio
King_of_Bio Aug. 18 at 2:40 PM
$TNYA This is a new bio...temper your expectations and expect volatility. I would NOT have this be my biggest investment yet...be SMART. Only invest what you're willing to lose.
0 · Reply
Minecraftbeers
Minecraftbeers Aug. 18 at 2:36 PM
$TNYA https://finance.yahoo.com/healthcare/articles/tenaya-therapeutics-eyes-q4-updates-080156311.html
0 · Reply
bdiddy366
bdiddy366 Aug. 18 at 2:23 PM
$TNYA is anyone worried about a potential reverse stock split? They cannot keep of these these expenses forever.
2 · Reply
Minecraftbeers
Minecraftbeers Aug. 18 at 2:19 PM
$TNYA several headlines advertising CMO and CEO selling stocks for tax withholding. That mixed with the Sub $1 and stock declining isn’t a good look. Hopefully we get some good news soon. Nonetheless I bought the dip. Keep on keeping on, no matter how bad it gets.
0 · Reply
Raumerica
Raumerica Aug. 18 at 1:15 PM
$TNYA If David Goeddel cuts and runs, I will as well. Until then, I will stick around. High institutional ownership that is increasing and I like the pipeline. 159 million market cap for 1 billion + potential in the short run… Positive TN201 and TN401 will catapult this stock.
1 · Reply
dig_THAT_girl
dig_THAT_girl Aug. 18 at 5:12 AM
$TNYA no bs, I am very new to investing . Went with biotech for the high risk high reward aspect. Four months in and I’m getting killed. Two stocks in particular, VNRX and PDSB have shit the bed. Altimmune well, whatever. I’ve put a lot into TNYA for various reasons. Yes I’ve done the DD. But, one of the most compelling reasons I believe in TNYA is based purely on gut instinct. Which ito some people is the worst reason for investing. But, assuming Biovic is a real human and not an AI bot, his zeal and investment in TNYA is compelling enough for me. That said, I’m pretty sure he’s not a bot because he laughs in Spanish. And only humans laugh naturally. So until he cuts and runs, I’m all in with my poultry 5500 shares. P.S. I’m retired on a pension and would prefer not to lose my investment, but fuck it, it’s biotech after all! LGMFrs!
2 · Reply
BIOVIC
BIOVIC Aug. 17 at 10:06 PM
$TNYA was searching for culprit on today’s distribution and the conclusion is it was technical. 13f q2 2026 dropped friday and today’s tape starts to make sense in reverse what actually happened between q1 and q2: renaissance +2.43M shares (+131%) marshall wace +2.10M (+149%) millennium +1.81M (+39%) citadel +367k common, doubled calls, cut puts adar1 +50k, dafna +300k new specialist biotech smart money — casdin, stonepine, burkehill, euclidean — all held flat through the sub-$1 crossing. nobody blinked one seller of size: empery -1.55M. that’s the pipe fund unwinding, been doing it for a year. not a thesis vote net institutional buying ~5-6M vs 1.6M sold. 3-4x buy/sell imbalance in the quarter tnya spent most of its life between .60 and 1.10 so today’s -3.85 on 4.28M vol while xbi was green wasn’t a big holder dumping on the 13f read. it was stops running under .72 then .70. algos, not fundamentals the smart books added into the weakness. i’m not going to sell into what they were buying #biovic nfa
1 · Reply
Minecraftbeers
Minecraftbeers Aug. 17 at 9:36 PM
$TNYA well I was up 22% YTD on my portfolio and TNYA is my biggest position as of this past spring/summer while DCA’n… now my portfolio is only up 0.16%, I’m back to where I started because of TNYA 😭😭😭 still holding still waiting still idk anymore lol
3 · Reply
Minecraftbeers
Minecraftbeers Aug. 17 at 8:49 PM
$TNYA https://www.marketbeat.com/instant-alerts/filing-gsa-capital-partners-llp-makes-new-197-million-investment-in-tenaya-therapeutics-inc-tnya-2026-08-17/
0 · Reply
BIOVIC
BIOVIC Aug. 17 at 8:03 PM
$TNYA eod. .70 -3.85 on 4.28M vol, biggest volume in weeks. range .68-.73, closed near the low. .68 held for now but bounce failed at .73 XBI +1.33 green, we diverged hard. sector day this wasnt, someone got out today. could be front running the raise cfo telegraphed, could be one seller done, tape will tell tomorrow .68 the line, break that and .65 next. thesis unchanged, tape is what tape is. accumulation happens in the boring, and today wasnt boring. HODL. #biovic nfa
0 · Reply
BIOVIC
BIOVIC Aug. 17 at 5:11 PM
$TNYA seems like sellers are exhausted. Come back up baby!
0 · Reply
Minecraftbeers
Minecraftbeers Aug. 17 at 3:23 PM
$TNYA
0 · Reply
Rolfthewild
Rolfthewild Aug. 17 at 2:57 PM
$TNYA Ibought the dip and if your crazy like me you did too. 🤪
2 · Reply
stock_x_pirate
stock_x_pirate Aug. 17 at 2:56 PM
$TNYA have no fear. the stock is testing lower support at the lower bollinger band. right now it is just trading on technicals. would think it be a good place to load.
2 · Reply
dig_THAT_girl
dig_THAT_girl Aug. 17 at 2:40 PM
$TNYA what a bummer
0 · Reply
eren1
eren1 Aug. 17 at 2:38 PM
$TNYA Do you have any comments on Biovic? @BIOVIC
2 · Reply
Psypsyd
Psypsyd Aug. 17 at 2:07 PM
$TNYA garbage-ing as usual #feelsbad
1 · Reply
Raumerica
Raumerica Aug. 17 at 10:54 AM
$TNYA Yes… The company has until the end of January to regain compliance.
1 · Reply